AbbVie Signs an Exclusive Worldwide Option and License Agreement with Alpine to Develop and Commercialize ALPN-101

Shots:

• Alpine to receive $60M up front, ~$805M as option exercise fee, development, regulatory and commercial milestones along with royalties on net sales of ALPN-101
• AbbVie to get an option to exclusively license ALPN-101, following exercising the option, AbbVie will conduct all future clinical development, manufacturing, and commercialization activities for ALPN-101
• During the option period, Alpine will conduct a P-II study in systemic lupus erythematosus. ALPN-101 is a first in class dual CD28/ICOS co-stimulation antagonist which demonstrated efficacy in multiple preclinical disease models, superior to blockade of either pathway alone

Click here to read full press release/ article | Ref: Alpine | Image: AbbVie